Reyes GU, Reyes HU, Quero HA, Reyes HD, Ortiz MM, Hernández PM, González SN

Language: Spanish
References: 21
Page: 6-12
PDF size: 205.57 Kb.

ABSTRACT

Objective: to determine the safety and effectiveness of the subcutaneous administering route of ribosomal fractions and proteoglycan of membrane in children with recurrent respiratory tract infection. Material and methods: a prospective, descriptive and observational study was carried out from january 1 to december 31, 2005, including infants aged one year and older with recurrent respiratory infections in a private clinic in Oaxaca, México. For this study, patients received 0.5 ml of solution containing membrane proteoglycans and ribosomal fractions, in a weekly basis by subcutaneous route for 4 weeks, with a boost 4 weeks later. The adverse reactions were evaluated as early and delayed, as well as the effectiveness related to the recurrent infections. Those who presented severe adverse reactions or did not complete the treatment were excluded. Results: for this study were included 117 patients. Those who presented adverse reactions were excluded (early local reaction, 6.32%; fever, 12). Only two were excluded because of severe adverse reactions. Its effectiveness was scored in 30 patients as +, ++ in 37, and total improvement or +++ in 42 patients. Eight patients remained without improvement, and worsening did not occurred, thus the total success was reached in 109 patients (93.16%) with a rate of small failure in only 7% of patients. Conclusions: membrane proteoglycans and ribosomal fractions by subcutaneous route are an excellent option in children with recurrent respiratory infections, with a high safety profile and minimum adverse reactions, and without clinical significance when present.

REFERENCES

1. Stiehm ER, Immunologic disorders in infants and children, 4 ed., Philadelphia, 1996, WB Saunders.

2. Rodríguez RS. Infecciones de vías respiratorias superiores en Pediatría. Diagnóstico y tratamiento de la faringoamigdalitis estreptocócica aguda. México DF, Editorial Imprecalli, 1989:pp 65-9.

3. Lovera D, López Pío. Faringitis estreptocócica. Rev Enf Infec Ped 2001;55:106-14.

4. Torales y T, Mascareñas de los Santos A. Infección de vías respiratorias superiores. En González SN (edit) Infectología Clínica Pediátrica 6ª. Edición. México. Editorial Trillas 1997 pp 69-90.

5. Rojas CC, Castañeda NJL, Chacón CE. Otitis media En: González SN. (edit) El paciente pediátrico infectado, guía para su diagnóstico y tratamiento 3ª edición México Trillas 1997 .p. 133-9.

6. Quian J, Iglesias D, Damico P, Galli A, Romero C, Machín F, Laje P, Esteban M, Pedreira W, Mogdascy C, Uriarte R. Investigación etiológica y tratamiento via oral de las neumonías adquiridas en la comunidad no complicadas, en niños mayores de un año Rev Enf Infec Ped. 2002; 62: 56-62.

7. Rodríguez RS Primer consenso de vacunación para la práctica pediátrica en México. Merck Sharp Dohme 2001 p. 5-7.

8. López OG, Maciel MB, Martínez OS, Mejia CF, López LJ, Rivera PJ, García BC, Huerta LJ. Prevalence of allergic diseases in México City Allergy Clin Inmunol Int 2000 (supp 2):100.

9. Vergara VJ, Peña EN, Samayoa OA, López PG, Huerta LJ. Asociación entre infección de vías aéreas superiores y asma alérgica en sujetos con y sin antecedentes heredofamiliares de atopia. Alergia Inmunol Pediatr 1997;6:47.

10. Clot J. Immunité anti-infectieuse. Mécanismes, facteurs, spécifiques et non spécifiques. Rev. Practicien (Paris) 1994;44:2505-12.

11. Avellavena PAE, Pirelli A, et al Simulation of citotoxic and non citotoxic functions of natural killer cells by bacterial membrane proteoglycans and ribosome. Int J Immunopharmacol 1989.

12. Laurent PH, Montain Y, Pacheco Y, et al. Etude in vivo de la leucocytaire au cours d »infections broncho-pulmonaires récidivants a pyogènes. A propos d’uncssai d’ immunotherapic avec Ribomunyl. Gaz Med France 1982;89 :1277-80.

13. Robert D, Quillon JP. Role of interferon in mice protection against influenza A virus by bacterial ribosomes together with membranal glycoproteins of Pneumoniae as adjuvant. Infect Immun.1979;26:515-9.

14. ETAV para vacunas específicas en: Eventos temporalmente asociados a la vacunación (ETAV). Manual de procedimientos técnicos 2002. Secretaría de Salud p. 85-8.

15. Saugier B, Mellet P, Van Kerckhoven A, et al. Study of the adjuvant effects of Ribomunyl on the influenza virus vaccine. European Academy of Allergology and Clinical Immunology; 1990.

16. Krachenbuhi JP, Neutra MR. Molecular and cellular basis of immune protection of mucosal surfaces. Physiol Rev 1992;72:853-79.

17. Castañeda JL, Chávez R. Estudio de eficacia de un tratamiento preventivo de tres meses de duración con derivados ribosomales en niños con infección respiratoria recurrente que asisten a guardería. Rev. Enf Inf Ped 2002;15(60):121-6.

18. Acosta AM, Muñoz MAC, Díaz MLA, Zapata DF. Eficacia y grado de aceptación del tratamiento preventivo con fracciones ribosomales en niños con infecciones respiratorias recurrentes. Rev Enf Inf Ped 2005;18(71):72-81.

19. Rodríguez OAR. Amoxiclav-Ribovac vs. ribovac-inmunoglobulina en niños con infección respiratoria alta recurrente. Alergia, Asma e Inmunología Pediátrica Vol. 10, num.3 mayo-junio 2001 pp. 104-118.

20. Hernández PM. Neumococo: resistencia y prevención editorial Rev Enf Infec Ped 2000;52: 361-2.

21. Michel PP, Reyes GU, Kutz de la Mora J. Puericultura en: La Salud del niño y del adolescente. Martínez y M (editor) 5ª Manual Moderno México. p 2005 p. 435-46.